Meeting Banner
Abstract #2786

31P and 1H MRS of Androgen-Independent and Androgen-Dependent Prostate Cancer Xenografts: Lonidamine Selectively Decreases Tumor Intracellular pH, Bioenergetics and Increases Lactate

Kavindra Nath1, David Nelson1, Dennis Leeper2, and Jerry Glickson1

1University of Pennsylvania, Philadelphia, PA, United States, 2Thomas Jefferson University, Philadelphia, PA, United States

Lonidamine (LND) effects were measured in vivo by 31P and 1H MRS in androgen-independent (PC3) and androgen-dependent (LNCaP) prostate cancer xenografts indicating a sustained and tumor-selective decrease in intracellular pH (pHi) and extracellular pH (pHe), and decrease in tumor bioenergetics (βNTP/Pi) by 75.0 % and 79.0 % in PC3 and LNCaP, respectively, relative to the baseline levels. Steady-state levels of tumor lactate were significantly increased ~ 2 fold at 60 min. post-LND. The decline of pHi, pHe, bioenergetics and increase in lactate produced increased therapeutic efficacy when LND was combined with other therapeutic interventions (chemotherapy, radiation, and hyperthermia).

This abstract and the presentation materials are available to members only; a login is required.

Join Here